Condition
Locally Advanced Clear Cell Renal Cell Carcinoma
Total Trials
3
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Recruiting2
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT03284385Phase 2Active Not Recruiting
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2
NCT06866262Phase 1RecruitingPrimary
Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
NCT06942104Phase 1Recruiting
Imaging of Solid Tumors Using 18F-TRX
Showing all 3 trials